[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1994

Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development

Author Affiliations

Cleveland, Ohio

 

edited by John W. Rippon and Robert A. Fromtling, 488 pp, with illus, $165, New York, NY, Marcel Dekker Inc, 1993.

Arch Dermatol. 1994;130(5):669. doi:10.1001/archderm.1994.01690050139030

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Cutaneous Antifungal Agents is a well-written, 29 chapter, multiauthored text that reviews select new antifungal agents with potential or current use in dermatology. The book is divided into five parts: (1) the morphalines; (2) allylamines (naftifine, terbinafine); (3) fluconazole; (4) itraconazole; and (5) compounds in development (nikkomycins and pneumocandins). Each chapter is written by basic scientists, and most authors are linked to the pharmaceutical company that developed the antifungal compound. Author selection was a logical choice by the editors, as each chapter is written by those most familiar with the antifungal drug, including in some cases individuals directly involved in the discovery of the compound. Only a couple of chapters are written by clinical dermatologists.

Each section has chapter topics that include the discovery and chemistry of the drug, preclinical data, mode of action, safety, and in vitro and in vivo activities. For each antifungal agent discussed, information stressed is

First Page Preview View Large
First page PDF preview
First page PDF preview
×